← Back
EnsiliTech
From open sourcesVaccines and biologics that do not need refrigeration
HealthTechSeedBristolFounded: 2021
About the company
EnsiliTech encases unstable biomolecules in a silica shell. This lets medicines withstand temperatures from −80 to +50 °C without relying on the cold chain. It is a British company based in Bristol, a University of Bath spinout incorporated in 2021. One of its four co-founders, CEO Asel Sartbaeva, was born in Kyrgyzstan. In August 2025 the company raised a £4.5M seed round led by Eos Advisory.
AI analysis of the idea
Prepared by AIFree vaccines and biologics from their dependence on the cold chain.
Strengths
- The cold chain is costly and often breaks, so the solution matters to rich and poor countries alike.
- The technology is patent-protected and already backed by specialist investors and grants.
Growth outlook
- The platform suits vaccines and other biologics alike, allowing many partnerships with drugmakers.
- A growing number of medicines needing refrigeration makes storage without the cold chain increasingly valuable.
This analysis was prepared by the Claude language model on Nov 5, 2026 from public data: the company profile, its website and publications.
Funding rounds
SeedAugust 2025
£4.5MEos AdvisoryLead, Calculus Capital, Empirical Ventures, Fink Family Office, QantX, Angel Investors Bristol, HERmesa, Penn Park Capital, chANGELS
Сумма в фунтах, как в источнике. Также участвовали частные ангелы.
Pre-seedJanuary 2023
£1.2MScience Angel SyndicateLead, Fink Family OfficeLead, QantX, Elbow Beach Capital, Innovate UK
Сумма в фунтах, как в источнике. Включает грант Innovate UK, его доля не раскрыта.
Startup news
Data sources
Is this your startup?
Update the data. Profiles confirmed by the company itself get a badge.
Tell us what to fix or add — and leave a contact for verification.